Accéder au contenu
Merck

Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.

The Journal of pathology (2014-06-04)
Alfonso Quintás-Cardama, Sean M Post, Luisa M Solis, Shunbin Xiong, Peirong Yang, Nanyue Chen, Ignacio I Wistuba, Ann M Killary, Guillermina Lozano
RÉSUMÉ

Deregulation of cell polarity proteins has been linked to the processes of invasion and metastasis. TRIM62 is a regulator of cell polarity and a tumour suppressor in breast cancer. Here, we demonstrate that human non-small cell lung cancer lesions show a step-wise loss of TRIM62 levels during disease progression, which was associated with poor clinical outcomes. To directly examine the role of Trim62 in development of lung cancer, we deleted Trim62 in a mutant K-Ras mouse model of lung cancer. In this context, haploinsufficiency of Trim62 synergized with a K-RasG12D mutation to promote invasiveness and disrupt three-dimensional morphogenesis, both of which are associated with epithelial-mesenchymal transitions. Re-expression of Trim62 reverted these phenotypes in tumour cell lines. Thus, Trim62 loss cooperates with K-Ras mutation in tumourigenesis and metastasis in vivo, indicating that decreased levels of TRIM62 may play an important role in the evolution of lung cancer.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Bleu de trypan solution, 0.4%, liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Trypan Blue, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Trypan Blue, Dye content 60 %, ≥80% (HPLC)
Sigma-Aldrich
Bleu de trypan solution, 0.4%, for microscopy
Sigma-Aldrich
Anticorps anti-protéine sécrétoire des cellules de Clara, serum, Upstate®
Sigma-Aldrich
MISSION® esiRNA, targeting human TRIM62
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Trim62